Founded in 2019, Beckley Psytech is a for-profit company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.
Total Funding: $114.2 M
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2C
Company Size: 26 to 50
Founded: 2019
Nov 2021
- Beckley Psytech Hired Dr Frank Wiegand, as Chief Medical Officer
Oct 2021
- Beckley Psytech Announced First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT
Aug 2021
- Beckley Psytech Raised $80M Funding
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Beckley Psytech
